Complete Response Letter BLA 125842 (Jul 9, 2025)

Summary

The FDA issued a Complete Response Letter for Capricor, Inc.'s Biologics License Application (BLA) for deramiocel, indicating that the application cannot be approved in its current form due to significant deficiencies in clinical data and lack of substantial evidence of effectiveness.

Key points

• The applicant must address the failure of the HOPE-2 study to demonstrate efficacy for its prespecified primary and secondary endpoints.
• The applicant must provide substantial evidence of effectiveness from adequate and well-controlled studies, as post hoc analyses were deemed insufficient.
• The applicant must conduct new adequate and well-controlled study(ies) with a primary objective of evaluating cardiac outcomes in deramiocel-treated patients with Duchenne muscular dystrophy (DMD) cardiomyopathy, compared to a randomized, concurrent control group over an appropriate duration.
• The applicant must address deficiencies related to Chemistry, Manufacturing, and Controls (CMC).
• The applicant must resubmit or withdraw the application within one year from the date of this letter (21 CFR 601.3(b)).
• Any resubmission must fully address all listed deficiencies; a partial response will not be processed as a resubmission.
• The HOPE-2 study failed to demonstrate efficacy for its prespecified primary and secondary endpoints. The application relies on post hoc analyses of HOPE-2 and HOPE-2-OLE, which are considered exploratory and hypothesis-generating, and thus insufficient to provide substantial evidence of effectiveness for the treatment of cardiomyopathy in DMD. The HOPE-2 study was not designed to assess cardiomyopathy, lacked sufficient prespecified baseline clinical data, and utilized numerous secondary/exploratory endpoints without appropriate multiplicity adjustment, leading to potentially spurious findings.
• The letter indicates unresolved deficiencies related to Chemistry, Manufacturing, and Controls, specifically mentioning 'CMC [Facility and Equipment]'. The detailed nature of these deficiencies is redacted in the provided text.

Cited reasons

• Lack of Substantial Evidence of Effectiveness for Proposed Indication
• Unspecified Chemistry, Manufacturing, and Controls (CMC) Deficiencies
• Labeling Review Pending Resolution of Clinical Deficiencies
• The Biologics License Application for deramiocel received a Complete Response Letter primarily due to a lack of substantial evidence of effectiveness for the proposed indication of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD). The primary clinical study failed its prespecified endpoints, and the reliance on post hoc, exploratory analyses was deemed insufficient to support approval. Additionally, there are unresolved Chemistry, Manufacturing, and Controls (CMC) deficiencies related to facility and equipment.

Recommended actions

• The applicant must address the failure of the HOPE-2 study to demonstrate efficacy for its prespecified primary and secondary endpoints.
• The applicant must provide substantial evidence of effectiveness from adequate and well-controlled studies, as post hoc analyses were deemed insufficient.
• The applicant must conduct new adequate and well-controlled study(ies) with a primary objective of evaluating cardiac outcomes in deramiocel-treated patients with Duchenne muscular dystrophy (DMD) cardiomyopathy, compared to a randomized, concurrent control group over an appropriate duration.
• The applicant must address deficiencies related to Chemistry, Manufacturing, and Controls (CMC).
• The applicant must resubmit or withdraw the application within one year from the date of this letter (21 CFR 601.3(b)).
• Any resubmission must fully address all listed deficiencies; a partial response will not be processed as a resubmission.

Deficiency summary

The Biologics License Application for deramiocel received a Complete Response Letter primarily due to a lack of substantial evidence of effectiveness for the proposed indication of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD). The primary clinical study failed its prespecified endpoints, and the reliance on post hoc, exploratory analyses was deemed insufficient to support approval. Additionally, there are unresolved Chemistry, Manufacturing, and Controls (CMC) deficiencies related to facility and equipment.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

BLA

Impact

Impact score

0.95

Estimated delay

365 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary reason for the Complete Response is the failure to demonstrate substantial evidence of effectiveness through adequate and well-controlled studies, relying instead on exploratory post hoc analyses. This fundamental clinical deficiency is compounded by unresolved CMC issues, indicating that the product's approvability is significantly hampered by both efficacy and manufacturing concerns.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%